Treatment and Outcomes of Pancreatic Cancer in Armenia: A Retrospective Study From Resource-Limited Settings
PURPOSEPancreatic cancer is one of the deadliest cancers in the world. In Armenia, it is 12th by incidence. The aim of this study is to evaluate treatment and outcomes of pancreatic cancer in Armenia during the past 12 years.METHODSThis is a retrospective study with data from three oncology centers...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Society of Clinical Oncology
2025-01-01
|
| Series: | JCO Global Oncology |
| Online Access: | https://ascopubs.org/doi/10.1200/GO.24.00217 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832577548280659968 |
|---|---|
| author | Elen Baloyan Davit Zohrabyan Liana Safaryan Armen Avagyan Lilit Harutyunyan Vardan Bardakhchyan Jemma Arakelyan Amalya Sargsyan Martin Harutyunyan Mariam Mailyan Gevorg Tamamyan Samvel Bardakhchyan |
| author_facet | Elen Baloyan Davit Zohrabyan Liana Safaryan Armen Avagyan Lilit Harutyunyan Vardan Bardakhchyan Jemma Arakelyan Amalya Sargsyan Martin Harutyunyan Mariam Mailyan Gevorg Tamamyan Samvel Bardakhchyan |
| author_sort | Elen Baloyan |
| collection | DOAJ |
| description | PURPOSEPancreatic cancer is one of the deadliest cancers in the world. In Armenia, it is 12th by incidence. The aim of this study is to evaluate treatment and outcomes of pancreatic cancer in Armenia during the past 12 years.METHODSThis is a retrospective study with data from three oncology centers in Armenia: “Muratsan” Hospital of Yerevan State Medical University, Mikaelyan institute of surgery, and Yeolyan Hematology and Oncology Center. The information was obtained from the medical records of the patients with pancreatic cancer treated at these centers during January 1, 2010-January 1, 2022. Log-rank test and Kaplan-Meier curves were used for survival analysis. Cox regression analysis was performed for identification of main prognostic factors.RESULTSOf 70 patients involved in the final analysis, 45.7% was female. The median age at diagnosis was 63 years. The median follow-up time was 11 months (range, 2-146). A total of 11.4% of patients had stage I-II, 27.1% had stage III, and 60% had stage IV disease. The main independent prognostic factor for overall survival (OS) was the TNM stage, whereas grade of the tumor was not significant. The median OS was 11 months (range, 2-169 months): In stages I-III, patients who had surgery (44.4%) lived significantly longer than those who did not (20 v 11 months; P = .008). Main chemotherapy regimens were 5-fluorouracil, oxaliplatin, folinic acid and irinotecan (41.4%) and gemcitabine plus capecitabine (38.6%). No significant survival difference was found between these groups (13 v 11 months; P = .162).CONCLUSIONSurvival of patients with pancreatic cancer in Armenia is dismal, not exceeding 1 year. Hopefully, further research in the field and new treatment modalities will improve the situation. |
| format | Article |
| id | doaj-art-a4cdc1c2e2134104aeef0e60f918918d |
| institution | Kabale University |
| issn | 2687-8941 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | American Society of Clinical Oncology |
| record_format | Article |
| series | JCO Global Oncology |
| spelling | doaj-art-a4cdc1c2e2134104aeef0e60f918918d2025-01-30T20:59:05ZengAmerican Society of Clinical OncologyJCO Global Oncology2687-89412025-01-011110.1200/GO.24.00217Treatment and Outcomes of Pancreatic Cancer in Armenia: A Retrospective Study From Resource-Limited SettingsElen Baloyan0Davit Zohrabyan1Liana Safaryan2Armen Avagyan3Lilit Harutyunyan4Vardan Bardakhchyan5Jemma Arakelyan6Amalya Sargsyan7Martin Harutyunyan8Mariam Mailyan9Gevorg Tamamyan10Samvel Bardakhchyan11Department of Oncology, Yerevan State Medical University, Yerevan, ArmeniaAdults Solid Tumors Chemotherapy Department, Yeolyan Hematology and Oncology Center, Yerevan, ArmeniaAdults Solid Tumors Chemotherapy Department, Yeolyan Hematology and Oncology Center, Yerevan, ArmeniaDepartment of Oncology, Yerevan State Medical University, Yerevan, ArmeniaDepartment of Oncology, Yerevan State Medical University, Yerevan, ArmeniaAlikhanyan National Science Laboratory, Yerevan, ArmeniaDepartment of Oncology, Yerevan State Medical University, Yerevan, ArmeniaAdults Solid Tumors Chemotherapy Department, Yeolyan Hematology and Oncology Center, Yerevan, ArmeniaAdults Solid Tumors Chemotherapy Department, Yeolyan Hematology and Oncology Center, Yerevan, ArmeniaAdults Solid Tumors Chemotherapy Department, Yeolyan Hematology and Oncology Center, Yerevan, ArmeniaDepartment of Oncology, Yerevan State Medical University, Yerevan, ArmeniaAdults Solid Tumors Chemotherapy Department, Yeolyan Hematology and Oncology Center, Yerevan, ArmeniaPURPOSEPancreatic cancer is one of the deadliest cancers in the world. In Armenia, it is 12th by incidence. The aim of this study is to evaluate treatment and outcomes of pancreatic cancer in Armenia during the past 12 years.METHODSThis is a retrospective study with data from three oncology centers in Armenia: “Muratsan” Hospital of Yerevan State Medical University, Mikaelyan institute of surgery, and Yeolyan Hematology and Oncology Center. The information was obtained from the medical records of the patients with pancreatic cancer treated at these centers during January 1, 2010-January 1, 2022. Log-rank test and Kaplan-Meier curves were used for survival analysis. Cox regression analysis was performed for identification of main prognostic factors.RESULTSOf 70 patients involved in the final analysis, 45.7% was female. The median age at diagnosis was 63 years. The median follow-up time was 11 months (range, 2-146). A total of 11.4% of patients had stage I-II, 27.1% had stage III, and 60% had stage IV disease. The main independent prognostic factor for overall survival (OS) was the TNM stage, whereas grade of the tumor was not significant. The median OS was 11 months (range, 2-169 months): In stages I-III, patients who had surgery (44.4%) lived significantly longer than those who did not (20 v 11 months; P = .008). Main chemotherapy regimens were 5-fluorouracil, oxaliplatin, folinic acid and irinotecan (41.4%) and gemcitabine plus capecitabine (38.6%). No significant survival difference was found between these groups (13 v 11 months; P = .162).CONCLUSIONSurvival of patients with pancreatic cancer in Armenia is dismal, not exceeding 1 year. Hopefully, further research in the field and new treatment modalities will improve the situation.https://ascopubs.org/doi/10.1200/GO.24.00217 |
| spellingShingle | Elen Baloyan Davit Zohrabyan Liana Safaryan Armen Avagyan Lilit Harutyunyan Vardan Bardakhchyan Jemma Arakelyan Amalya Sargsyan Martin Harutyunyan Mariam Mailyan Gevorg Tamamyan Samvel Bardakhchyan Treatment and Outcomes of Pancreatic Cancer in Armenia: A Retrospective Study From Resource-Limited Settings JCO Global Oncology |
| title | Treatment and Outcomes of Pancreatic Cancer in Armenia: A Retrospective Study From Resource-Limited Settings |
| title_full | Treatment and Outcomes of Pancreatic Cancer in Armenia: A Retrospective Study From Resource-Limited Settings |
| title_fullStr | Treatment and Outcomes of Pancreatic Cancer in Armenia: A Retrospective Study From Resource-Limited Settings |
| title_full_unstemmed | Treatment and Outcomes of Pancreatic Cancer in Armenia: A Retrospective Study From Resource-Limited Settings |
| title_short | Treatment and Outcomes of Pancreatic Cancer in Armenia: A Retrospective Study From Resource-Limited Settings |
| title_sort | treatment and outcomes of pancreatic cancer in armenia a retrospective study from resource limited settings |
| url | https://ascopubs.org/doi/10.1200/GO.24.00217 |
| work_keys_str_mv | AT elenbaloyan treatmentandoutcomesofpancreaticcancerinarmeniaaretrospectivestudyfromresourcelimitedsettings AT davitzohrabyan treatmentandoutcomesofpancreaticcancerinarmeniaaretrospectivestudyfromresourcelimitedsettings AT lianasafaryan treatmentandoutcomesofpancreaticcancerinarmeniaaretrospectivestudyfromresourcelimitedsettings AT armenavagyan treatmentandoutcomesofpancreaticcancerinarmeniaaretrospectivestudyfromresourcelimitedsettings AT lilitharutyunyan treatmentandoutcomesofpancreaticcancerinarmeniaaretrospectivestudyfromresourcelimitedsettings AT vardanbardakhchyan treatmentandoutcomesofpancreaticcancerinarmeniaaretrospectivestudyfromresourcelimitedsettings AT jemmaarakelyan treatmentandoutcomesofpancreaticcancerinarmeniaaretrospectivestudyfromresourcelimitedsettings AT amalyasargsyan treatmentandoutcomesofpancreaticcancerinarmeniaaretrospectivestudyfromresourcelimitedsettings AT martinharutyunyan treatmentandoutcomesofpancreaticcancerinarmeniaaretrospectivestudyfromresourcelimitedsettings AT mariammailyan treatmentandoutcomesofpancreaticcancerinarmeniaaretrospectivestudyfromresourcelimitedsettings AT gevorgtamamyan treatmentandoutcomesofpancreaticcancerinarmeniaaretrospectivestudyfromresourcelimitedsettings AT samvelbardakhchyan treatmentandoutcomesofpancreaticcancerinarmeniaaretrospectivestudyfromresourcelimitedsettings |